Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Financial Outlook | Learn about Terns' strong cash position of $373 million, funding operations into 2028, with an average analyst price target of $20 |
Market Potential | Analysts project a 27% to 62% stock price increase based on TERN-601's competitive efficacy in the lucrative obesity treatment market |
Clinical Breakthroughs | Delve into TERN-701's impressive Phase 1 results for CML, showcasing efficacy and safety advantages over existing therapies |
Promising Pipeline | Explore Terns Pharmaceuticals' innovative treatments for chronic liver diseases, cancer, and obesity, with lead candidates TERN-701 for CML and TERN-601 for obesity |
Metrics to compare | TERN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTERNPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.9x | −0.3x | −0.5x | |
PEG Ratio | −0.21 | 0.00 | 0.00 | |
Price / Book | 0.8x | 0.2x | 2.6x | |
Price / LTM Sales | - | 1.8x | 3.0x | |
Upside (Analyst Target) | - | 157.7% | 52.7% | |
Fair Value Upside | Unlock | 9.0% | 7.6% | Unlock |